Founded in 2022 after eight years of research and development, Kitea Health is pioneering micro-implantable technology for the brain. Their initial focus is hydrocephalus – a condition affecting more than one million people in the United States – where today's standard of care still relies on invasive, intermittent monitoring that too often leads to repeated hospitalisations and avoidable complications.

Kitea’s solution aims to enable long-term, remote pressure monitoring – with the potential to fundamentally change how how chronic conditions are managed.

We backed Kitea early, recognising a rare combination of deep scientific rigour and genuine clinical urgency.

The team has already achieved what few medical device companies ever do: placing the world's first micro-implantable device in the human brain, completing a clinical trial at Auckland City Hospital, and earning FDA Breakthrough Device Designation – a status reserved for medical technologies that address serious health needs. Their acceptance into the FDA's Total Product Life Cycle Advisory Program (TAP) further accelerates their path to market.

Kitea has raised over $10 million in seed funding and grants, followed by a $14 million Pre-Series A round, reflecting the strong conviction behind their mission.